A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs BAY 1093884 (Primary) ; BAY 1093884 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 05 Jul 2017 Planned End Date changed from 31 Jan 2018 to 15 May 2018.
- 05 Jul 2017 Planned primary completion date changed from 20 Dec 2017 to 15 Mar 2018.
- 10 Jun 2017 Biomarkers information updated